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ABSTRACT
Preclinical studies show that the glucagon-like peptide-1 (GLP-1) receptor 
antagonist, exendin (9-39), can reduce acute emesis induced by cisplatin. In the 
present study, we investigate the effect of exendin (9-39) (100 nmol/24 h, i.c.v), on 
cisplatin (5 mg/kg, i.p.)-induced acute and delayed emesis and changes indicative 
of ‘nausea’ in ferrets. Cisplatin induced 37.2 ± 2.3 and 59.0 ± 7.7 retches + vomits 
during the 0-24 (acute) and 24-72 h (delayed) periods, respectively. Cisplatin also 
increased (P<0.05) the dominant frequency of gastric myoelectric activity from 9.4 ± 
0.1 to 10.4 ± 0.41 cpm and decreased the dominant power (DP) during acute emesis; 
there was a reduction in the % power of normogastria and an increase in the % power 
of tachygastria; food and water intake was reduced. DP decreased further during 
delayed emesis, where normogastria predominated. Advanced multifractal detrended 
fluctuation analysis revealed that the slow wave signal shape became more simplistic 
during delayed emesis. Cisplatin did not affect blood pressure (BP), but transiently 
increased heart rate, and decreased heart rate variability (HRV) during acute emesis; 
HRV spectral analysis indicated a shift to ‘sympathetic dominance’. A hyperthermic 
response was seen during acute emesis, but hypothermia occurred during delayed 
emesis and there was also a decrease in HR. Exendin (9-39) did not improve feeding 
and drinking but reduced cisplatin-induced acute emesis by ~59 % (P<0.05) and 
antagonised the hypothermic response (P<0.05); systolic, diastolic and mean arterial 
BP increased during the delayed phase. In conclusion, blocking GLP-1 receptors in 
the brain reduces cisplatin-induced acute but not delayed emesis. Restoring power 
and structure to slow waves may represent a novel approach to treat the side effects 
of chemotherapy.
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INTRODUCTION
The treatment of cancer with cisplatin–based 
therapies is documented to be associated with the side 
effects of nausea and emesis (retching and vomiting). 
Current treatment guidelines include combining 
5-hydroxytryptamine3 (5-HT3) receptor (e.g. ondansetron, 
palonosetron) and tachykinin neurokinin1 (NK1) 
receptor antagonists (e.g. aprepitant, netupitant) with a 
glucocorticoid, such as dexamethasone [1]. However, not 
all patients are completely protected [2]. Investigations 
into the contribution of novel mechanisms to the emetic 
reflex are required to identify pathways resistant to 
conventional anti-emetic therapy [3].
5-HT3 and tachykinin NK1 receptors can be found in 
brain areas and afferent systems involved in emesis control 
including the area postrema (AP), nucleus tractus solitarius 
(NTS) and abdominal vagal neurones, representing logical 
sites to target drugs to inhibit emesis [3]. Glucagon-like 
peptide-1 (GLP-1) receptors are also distributed in the 
same pathways [4, 5], but also in more rostral brain 
areas (e.g. amygdala, hypothalamus) [4–6], linked to 
a modulation of biomarkers associated with nausea 
including plasma vasopressin [7]; gastric myoelectric 
activity (GMA) [8, 9]; and heart rate variability (HRV) 
[10]. Not surprisingly, GLP-1 receptor agonists including 
exenatide (synthetic exendin-4) and liraglutide (used for 
the treatment of type 2 diabetes) can cause nausea and 
emesis in man [11].
Rodents are incapable of emesis [12] but have 
been used to identify sites of action of GLP-1 agonists 
to induce gastric malaise indicating the involvement of 
forebrain and hindbrain systems (see below). The effect 
of the GLP-1 receptor agonist, exendin-4, to cause pica 
(the consumption of a substance without nutritional value, 
which is presumed to be an index of emesis) in rats is 
not prevented by abdominal vagotomy [13], although 
activation of GLP-1 receptors in the NTS mediate 
reduction in food intake [14]. Interestingly, the GLP-1 
receptor antagonist, des-His1-Glu9-exendin-4, attenuates 
LiCl-induced conditioned taste avoidance and anorexia 
by mechanisms involving the AP, NTS, and lateral 
parabrachial nucleus [15, 16] demonstrating several 
sites of action within the brain to modulate malaise and 
aversive mechanisms.
Studies using Suncus murinus (house musk shrew) 
indicate that intracerebroventricularly (i.c.v.) administered 
exendin-4 is associated with emesis and an inhibition 
of food and water intake, reduced locomotor activity, 
and increases of c-Fos expression in the AP and NTS, 
hypothalamus and amygdala [17]. Only the emetic effect 
of exendin-4 and increases of c-Fos in the brainstem and 
hypothalamus were reversed by blocking GLP-1 receptors 
with the GLP-1 receptor antagonist, exendin (9-39) [17]. 
Further studies demonstrated that exendin-4-induced 
emesis in Suncus murinus is not prevented by ondansetron, 
or the NK1 receptor antagonist, CP-99,994, suggesting that 
GLP-1 receptor pathway(s) involved in emesis and feeding 
may be resistant to the conventional anti-emetics used in 
the treatment of chemotherapy-associated side effects [5].
The ferret has been used extensively for research 
into novel approaches to anti-emesis, particularly in 
relation to anti-cancer chemotherapy and to identify 
the emetic liability of novel chemical entities; in both 
settings the findings have had translational value [18–
21]. We have reported previously, using the ferret, that 
the hypoglycaemic and anorectic effects of exendin-4 
administered peripherally (100 nmol/kg, s.c.) were 
associated with a reduction of HRV and when emesis 
occurred, it was associated with effects on GMA 
manifested as bradygastria and reduced power [5], 
consistent with changes occurring during nausea in man 
induced by other stimuli [10, 22, 23]. We also showed 
that exendin-4 administered i.c.v. had similar effects 
to s.c. exendin-4 on GMA and HRV, but additionally 
hypertension and tachycardia also occurred [24]. The 
pattern of c-Fos activation following i.c.v. exendin-4 
indicated that emesis is reliant on the brainstem, but 
‘behaviours indicative of nausea’ most likely involve more 
rostral brain nuclei [25].
Exendin (9-39) administered i.c.v. antagonises the 
early emesis and associated increase in c-Fos in the dorsal 
vagal complex and the paraventricular hypothalamus 
induced by cisplatin in Suncus murinus [5]. However, no 
studies using a species capable of emesis have investigated 
the anti-emetic potential of GLP-1 receptor antagonists 
against both acute and delayed phases of cisplatin-induced 
emesis. Therefore, the present study was designed to 
investigate the anti-emetic potential of exendin (9-39) 
infused continuously using the well-characterised ferret 
model of acute and delayed emesis induced by cisplatin 
[26]. In addition to emesis, using radiotelemetry, the 
effects of cisplatin alone or with exendin (9-39) on GMA, 
cardiovascular function, body temperature, food and 
water intake were also recorded to access data that may be 
relevant to mechanisms underlying nausea [24, 25].
It is clear that GMA recordings have a visually 
apparent ‘slow-wave’ structure that changes in humans 
reporting nausea [23] and in animals given emetic stimuli 
[25, 27, 28]. However, these features may be lost during 
conventional signal processing techniques (e.g. fast Fourier 
transformation; FFT) to produce an electrogastrogram. 
Therefore, we applied multifractal detrended fluctuation 
analysis (MFDFA) to the telemetric recordings to examine 
if slow wave shape had been changed following cisplatin 
[29]. Fractal analyses have been used in other areas of 
signal processing to differentiate between healthy and 
pathological conditions (e.g. [30, 31]). Hence, we applied 
MFDFA to analysis of the GMA to more fully characterise 
the gastric effects of cisplatin during the acute and delayed 
phase of emesis and the involvement of GLP-1 receptors.
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RESULTS
General comments
Recovery of animals from surgery was generally 
uneventful and they ate and drank normally within the first 
day following the implantation of transmitters. However, 
one animal assigned to the Ex-9 + Cisplatin treatment 
group developed a suspected bladder infection, so it 
was excluded from the study. An implanted transmitter 
malfunctioned in an animal that was assigned to the Ex-9 
+ Cisplatin treatment group and therefore its telemetric 
data could not be recorded.
Effect of an i.c.v. infusion of exendin (9-39) (100 
nmol/24 h) or saline (10 μl/h) on cisplatin (5 mg/
kg, i.p.)-induced acute and delayed emesis
In the vehicle-treated animals, cisplatin induced 
emesis following a median latency of 3.5 h (range 2.2-5.2 
h). The response occurring during the acute (0-24 h) phase 
consisted of 37.2 ± 2.3 episodes and comprised 246.7 ± 
29.3 retches and 26.3 ± 0.8 vomits. The response occurring 
during the delayed (24-72 h) phase consisted of 59.0 ± 7.7 
episodes and comprised 372.8 ± 59.4 retches and 38.8 ± 
6.2 vomits. The infusion of exendin (9-39) did not affect 
the latency to the first episode (exendin (9-39)-treated 
animals, median latency = 4.6 h; range 3.4-8.5 h; P>0.05) 
but did significantly reduce the number of episodes of 
retching and/or vomiting, and number of retches + vomits 
during the acute phase by 39.5 and 59.3 %, respectively 
(P<0.05; Figure 1); the number of retches was not affected 
(a non-significant 43.3 % reduction was recorded; P>0.05, 
Figure 1). Exendin (9-39) did not affect the number of 
episodes or the number of retches or vomits during the 
delayed phase (modest 15-26 % non-significant reductions 
were observed; P>0.05, Figure 1).
Effect of an i.c.v. infusion of exendin (9-39) (100 
nmol/24 h) or saline (10 μl/h) on GMA in animals 
treated with cisplatin (5 mg/kg, i.p.)
Prior to randomization to the treatment groups, the 
baseline GMA recordings (-24-0 h) revealed a dominant 
frequency (DF) of 9.4 ± 0.1 cpm; 12.1 ± 0.5% of power 
was in the bradygastric range, 68.4 ± 0.5% of power was 
in the normogastric range, and 13.0 ± 0.4% of power was 
in the tachygastric range (pooled data, n = 10). In the 
saline infusion control group, cisplatin caused a transient 
increase in DF (to ~ 10.8 cpm) and a 50 % decrease in 
dominant power (DP) during the first 8 h following cisplatin 
injection; there was with a 35.9 % decrease in the % power 
of normogastria and a 167.2 % increase in the % power of 
tachygastria (P<0.05; n = 6, Figure 2 and Figure 3). After 
12 h, when the initial acute phase of emesis had begun to 
subside there was a decrease in DP (to ~ 0.003 mV2), with 
a 74.5 % decrease in the % power of bradygastria (P<0.05; 
n = 6, Figure 3 and Figure 4); normogastria (~80 %) then 
dominated for the remainder of the recording period, and the 
% power of tachygastria was ~10 %. The i.c.v. infusion of 
exendin (9-39) failed to affect the changes in GMA caused 
by cisplatin when analysed using conventional statistical 
approaches (P>0.05; n = 4-6, Figure 3 and Figure 4).
Application of MFDFA to the same data 
sets revealed that the baseline (-24-0 h) data had a 
multifractality magnitude of 0.791 ± 0.02 (arbitrary units). 
In the saline infusion group, cisplatin injection had no 
effect on multifractality during the 0-8, or 0-24 h periods 
(P>0.05). However, cisplatin decreased significantly the 
magnitude of the multifractality in the 24-48 h and 48-72 
h periods, by 13.6 and 21.0 %, respectively (P<0.05; n = 
4-6, Figure 5). The i.c.v. infusion of exendin (9-39) failed 
to affect the changes of multifractality magnitude induced 
by cisplatin (P>0.05; n = 4-6, Figure 5).
Effect of an i.c.v. infusion of exendin (9-39) (100 
nmol/24 h) or saline (10 μl/h) on bodyweight, 
food and water intake, in animals treated with 
cisplatin (5 mg/kg, i.p.)
Before drug administration, body weight was 1.53 ± 
0.07 kg and food and water intake was 33.46 ± 2.78 and 
80.21 ± 9.06 g/kg (pooled data, n = 10), respectively. In 
the saline group, cisplatin reduced body weight (-4.85 ± 
0.54 % at t = 24 h, -8.89 ± 0.48 % at t = 48 h and -13.39 
± 0.69 % at t = 72 h), food (-88.15 ± 2.20 % at 0-24 h, 
-98.6 ± 1.34 % at t = 24-48 h and -100 % at t = 48-72 h) 
and water intake (-74.11 ± 8.52 % at t = 0-24 h, -88.22 
± 4.76 % at t = 24-48 h and -83.90 ± 9.16 % at t = 48-
72 h; P<0.05; n = 6, Table 1); these reductions were not 
prevented by exendin (9-39) (P>0.05; n =4-6, Table 1).
Effect of an i.c.v. infusion of exendin (9-39) (100 
nmol/24 h) or saline (10 μl/h) on cardiovascular 
homeostasis and body temperature in animals 
treated with cisplatin (5 mg/kg, i.p.)
During baseline recordings (-24-0 h), arterial blood 
pressure (BP) was 116.8 ± 0.6 mmHg (systolic BP 155.6 ± 
0.7 mmHg; diastolic BP 97.3 ± 0.5 mmHg; pulse pressure: 
58.3 ± 0.3 mmHg) (pooled data, n = 10); heart rate (HR) 
and HRV were 249.6 ± 1.3 bpm and 0.0408 ± 0.0008 
(arbitrary units), respectively (pooled data, n = 10); core 
body temperature (CBT) was 38.4 ± 0.1 °C (pooled data, 
n = 10). In the saline group, cisplatin injection caused a 
transient increase in HR and CBT (an increase of ~1.9 °C 
was observed; P<0.05) with a ~30 % decrease in HRV 
during the first 8 h following cisplatin administration 
(P<0.05; n = 6, Figure 6); there was also an increase in HR 
(~ up to 50 bpm) and a decrease in HRV (a ~ 25 % fall) 
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Figure 1: Effect of an i.c.v. infusion of saline (10 μl/h) or exendin (9-39) (100 nmol/24 h) on emesis induced by cisplatin 
(5 mg/kg, i.p.). Profiles of emesis are shown in (A) and (B); latency to the first emetic episode (C); number of episodes of emesis during 
the 0-24 h (acute phase) (D) and 24-72 h (delayed phase) (E) are also shown. Data represents the mean ± SEM of 4-6 animals. Sal = saline, 
Ex-9 = exendin (9-39). Significant differences between Sal and Ex-9 groups are shown as *P<0.05 (unpaired t-test).
Figure 2: Running spectrum analysis (RSA) of gastric myoelectric activity (GMA) in the vehicle-control ferret that 
received cisplatin (5 mg/kg, i.p.). (A) RSA of GMA from start of baseline recording 24 h prior to cisplatin administration to 72 h after 
cisplatin administration; (B) an expanded view of the RSA from 4 h before cisplatin injection to 8 h post-cisplatin injection. DF = dominant 
frequency, DP = dominant power. This animal exhibited emesis after a latency of 2.52 h; it had 13 episodes of emesis during the first 8 h 
period (during the 0-24 h and 24-72 h periods, it had 37 and 26 episodes of emesis, respectively). Note the decrease in DP and increase in 
DF following cisplatin administration (arrowed boxes).
A B
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during the acute phase of emesis (0-24 h) (P<0.05; n = 6, 
Figure 6). As for HRV, a more detailed analysis showed 
that compared to baseline (0-24 h prior to cisplatin: low 
frequency (LF) = 394.9±15.9 ms2; high frequency (HF) 
= 1347.0±73.2 ms2, and LF/HF = 0.3079±0.005, arbitrary 
that cisplatin caused significant falls in LF (~ 40% fall; 
P<0.05) and HF (~ 55% fall; P<0.01) translating to an 
overall 20 % increase in the LF/HF ratio during the acute 
phase but not delayed phase (Figure 7). During the delayed 
phase there was a decrease in HR and also a decrease in 
CBT (~ 1.5 °C fall) compared with baseline recordings 
at t = -24-0 h (P<0.05; n = 6, Figure 6). There were no 
Figure 3: Effect of an i.c.v. infusion of saline (10 μl/h; open circles) or exendin (9-39) (100 nmol/24h; filled circles) on 
gastric myoelectric activity in animals given cisplatin cisplatin (5 mg/kg, i.p.). (A) DF, (B) percentage change of DF over 24 
h, (C) DP, (D) percentage change of DP over 24 h, (E) bradygastria (%), (F) percentage change of bradygastria over 24 h, (G) normogastria 
(%), and (H) percentage change of normogastria over 24 h, (I) tachygastria (%), and (J) percentage change of tachygastria over 24 h are 
shown. Sal = saline, Ex-9 = exendin (9-39), DF = dominant frequency, DP = dominant power. Data represents the mean ± SEM of 4-6 
animals. Significant differences relative to baseline recordings of the respective treatment groups are shown as #P<0.05 (one-way ANOVA).
Oncotarget98696www.impactjournals.com/oncotarget
major effects of cisplatin treatment on BP (P>0.05; n = 
6, Figure 6). The i.c.v. infusion of exendin (9-39) had no 
effect on any of the parameters recorded during the acute 
(0-24 h) phase, but caused an increase in systolic BP, 
diastolic BP and mean arterial BP during the delayed (24-
72 h) phase compared with saline group (P<0.05, Figure 
6). Exendin (9-39) failed to prevent the changes in HR and 
HRV (including LF, HF and LF/HF) caused by cisplatin 
(P>0.05; n = 4-6; Figure 6 and Figure 7). However, 
exendin (9-39) partially prevented the hypothermia 
caused by cisplatin compared with saline group during the 
delayed phase (P<0.05; n = 4-6, Figure 6I and 6J).
DISCUSSION
This study is the first to characterise GMA, 
cardiovascular parameters (HRV, BP) and temperature 
throughout both the acute and delayed phases of 
cisplatin-induced emesis in an animal model with proven 
translational value [19]. Cisplatin clearly affected both the 
power and frequency of gastric slow waves and applying 
the MFDFA for the first time to analyze the gastric 
effects of a cancer chemotherapy agent revealed that the 
magnitude of the multifractality of the structure of the 
slow waves was reduced in the delayed phase. The present 
Figure 4: Representative traces of gastric myoelectric activity recordings in a ferret that had received cisplatin (5 mg/
kg, i.p.). This animal exhibited emesis after 2.52 h. Filled dots indicate episodes of retching and/or vomiting during 1 h period.
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investigations are also the first to reveal the differential 
action of the GLP-1 receptor antagonist, exendin (9-39), to 
reduce acute but not delayed emesis induced by cisplatin. 
The findings are discussed below in detail together with 
the related effects on core body temperature and the 
cardiovascular system.
Figure 5: Multifractal detrended fluctuation analysis (MFDFA). (A) Generalized Hurst exponent h(q) vs. order q, and (B) 
dimension of subset series f(α) vs. Singularity strength α for gastric myoelectric activity in one ferret during four different time periods: pre-
cisplatin(-24-0 h) and post-cisplatin-Sal (0-24 h, 24-48 h, 48-72 h); (C) the width of the multifractal spectrum (Δα) of four different periods 
(-24-0 h, 0-24 h, 24-48 h, 48-72 h) in Sal and Ex-9 are shown, and data represents the mean ± SEM of 4-6 animals. Sal = saline, Ex-9 = 
exendin (9-39). Significant differences relative to baseline recordings of the respective treatment groups are shown as #P<0.05, ##P<0.01; 
no significant differences were found between Sal and Ex-9 groups (one-way ANOVA or two-way ANOVA as appropriate).
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Cisplatin induced emesis
The acute emetic response to cisplatin in the 
ferret is primarily by a release of 5-HT from intestinal 
enterochromaffin cells and activation of 5-HT3 receptors 
on the peripheral terminals of abdominal afferents 
projecting to the NTS (for reviews including evidence 
from other species [32]). It is during the initial phase of 
cisplatin-induced emesis that i.c.v. exendin (9-39) reduced 
emesis by ~40 % indicating involvement of central 
GLP-1 receptors in the emetic response to this cancer 
chemotherapeutic agent. GLP-1 receptors in the brainstem 
(AP and NTS) are implicated in the emetic response [17, 
25]. Previous acute studies in Suncus murinus showed 
that exendin (9-39) antagonised the early emetic response 
to cisplatin and also the associated increases of c-Fos 
expression in the NTS, AP, dorsal motor nucleus of the 
vagus nerve, and paraventricular hypothalamus [17]. 
Activation of abdominal vagal afferents by cisplatin is 
the most likely mechanism by which the central GLP-
1 pathways are activated in this acute phase. In the 
ferret, the peripherally acting emetic agents LiCl and 
cholecystokinin both activated GLP-1-positive neurones 
in the NTS [33]. In addition, in rats there is evidence that 
stimulation of 5-HT3 receptors located on abdominal vagal 
afferents drive the release of GLP-1 in approximately 20-
30 % of neurons in the NTS following gastric distension 
[34]. The reduction of the acute emetic response by ~59% 
with exendin (9-39) implies that either the dose used was 
not fully efficacious, despite using an infusion, or more 
likely that other central transmitters such as substance P 
are also implicated (for review see [35]).
Cisplatin and gastric myoelectric activity
In conscious ferrets during short duration recording, 
cisplatin decreased the % power of normogastria (~26 
%) and increased the % power of bradygastria, without 
modifying DF; these changes were most apparent 
during the first 2-3 h of 4 h total recording time and 
were associated with periods of emesis [28]. A study 
in conscious dogs showed that cisplatin (1.2 mg/kg, 
i.v.) interrupted gastric and intestinal inter-digestive 
myoelectric activity with the latency for onset of 
myoelectric changes being ~11 min less than for the 
onset of emesis [36] and the myoelectric changes lasting 
for at least 24 h. Another dog study found that cisplatin 
(1.5 mg/kg, i.v.) decreased by 22 % the time that GMA 
frequency was in the normal 4-6 per min range (methods 
to determine DF and associated parameters were not 
clearly defined) leading the investigators to conclude 
that dysrhythmia had occurred during their 6 h recording 
session [27]; however, this conclusion was based on a 
simplistic method of analysis, only assessing a shift to 
bradygastria or tachygastria, without assessing the power 
of the slow waves, or if the slow waves were in fact 
‘disordered’. A similar study in dogs showed an increase 
in gastric dysrhythmia for a period of 6 h following 
cisplatin [37].
We initially used conventional analytical techniques 
(FFT, power partitioning) to establish the effects of 
cisplatin 5 mg/kg, i.p. on GMA. We found that cisplatin 
induced an increase in DF, with increases in tachygastria 
during the first 8 h; this was balanced by a corresponding 
decrease in normogastria. In contrast to the acute phase 
emesis, the GMA changes were unaffected by central 
exendin (9-39) indicating that unlike emesis the GMA 
response to cisplatin does not involve central GLP-1 
receptors.
During the delayed emesis phase (24-72 h), 
conventional analytical techniques did not reveal further 
changes in the DF of the GMA: the power partition for 
normogastria predominated, suggesting that cisplatin had 
no effect on gastric slow wave rhythm during the delayed 
phase of emesis. However, MFDFA of 24 h epochs of data 
revealed a reduction in the magnitude of the multifractality 
indicative of reduced complexity in the form of the slow 
wave and an increased regularity. We were initially 
cautious to not over interpret the findings, since this is the 
first study where MFDFA has been applied to GMA. Yet 
the differences in slow wave structure were qualitatively 
visually apparent and did not appear to involve noise.
The antral electrodes are capable of detecting extra-
antral signals so digital off-line filtering was applied 
between 0-0.3 Hz (0-18 cycles per min (cpm)). GMA 
Table 1: Effect of an i.c.v. infusion of saline or exendin (9-39) (100 nmol/24 h) on body weight, food intake and water 
intake when animals received cisplatin
Body weight (% change) Food intake (% change) Water intake (% change)
Sal + Cisplatin Ex-9 + Cisplatin Sal + Cisplatin Ex-9 + Cisplatin Sal + Cisplatin Ex-9 + Cisplatin
Baseline 0 ± 0% 0 ± 0% 0 ± 0% 0 ± 0% 0 ± 0% 0 ± 0%
0-24 h -4.85 ± 0.54%### -5.12 ± 1.04%### -88.15 ± 2.19%### -83.99 ± 2.98%### -74.11 ± 8.52%### -67.37 ± 4.68%###
24-48 h -8.89 ± 0.48%### -9.57 ± 1.27%### -99.66 ± 1.34%### -98.66 ± 0.98%### -88.22 ± 4.76%### -79.87 ± 8.40%###
48-72 h -13.39 ± 0.70%### -14.75 ± 1.92%### -100 ± 0%### -100 ± 0%### -83.90 ± 5.16%### -85.11 ± 5.53%###
Data represents the mean ± SEM of 4-6 animals. Sal = saline, Ex-9 = exendin (9-39). Significant differences relative to baseline of the 
respective treatment groups are shown as ###P<0.001 (one-way ANOVA).
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Figure 6: Effect of an i.c.v. infusion of saline (10 μl/h; open circles) or exendin (9-39) (100 nmol/24 h; closed circles) on 
systolic blood pressure (BP), diastolic BP, heart rate (HR), heart rate variability (HRV) and core body temperature 
when animals received cisplatin (5 mg/kg, i.p.). (A) Systolic BP, (B) percentage change of systolic BP over 24 h, (C) diastolic BP, 
(D) percentage change of diastolic BP over 24 h, (E) HR, (F) percentage change of HR over 24 h, (G) HRV, (H) percentage change of HRV 
over 24 h, (I) core body temperature, (J) percentage change of core body temperature over 24 h are shown. Sal = saline, Ex-9 = exendin 
(9-39). Data represents the mean ± SEM of 4-6 animals. Significant differences relative to baseline recordings of the respective treatment 
groups are shown as #P<0.05; significant differences between Sal and Ex-9 groups are shown as *P<0.05, **P<0.01 (one-way ANOVA or 
two-way ANOVA as appropriate).
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manifests as slow waves is a summation of voltages 
coming from interstitial cells of Cajal (ICC; [38, 39]) 
and smooth muscle [40]. Gastric slow wave can also be 
modulated by stretch [41], temperature [42], hormones 
(e.g. vasopressin [43]), and the autonomic system [39] 
via effects on the ICCs and smooth muscle. Whilst there 
is no evidence for a direct action of cisplatin on ICCs or 
smooth muscles, in humans cisplatin can cause cardiac 
arrhythmia with a direct effect on cardiac sodium channels 
implicated [44]. In isolated dorsal root ganglion neurones, 
cisplatin in the clinical concentration range (1-10 μM) 
decreased input conductance and increased excitability 
[45]. Evidence was presented for effects of cisplatin on 
voltage activated K+ and Ca++ currents and Ca++ activated 
Cl- conductance [46]. Taking these observations together 
with the data on the diversity of conductance in ICCs [47], 
we hypothesise that cisplatin has a direct effect on ICCs 
leading to a simplification of their structure (reflected in 
the MFDFA). However, as the major effect of cisplatin on 
GMA revealed by MFDFA occurred in the delayed phase, 
it is possible that by this time damage is occurring to the 
enteric nervous system and is responsible for the effects. 
In rats treated with a single dose of cisplatin, gastric iNOS, 
L-citrulline and Ca++ calmodulin complex were reduced 
by 3 days [48] and in mice treated with oxaliplatin both 
Figure 7: Effect of an i.c.v. infusion of saline (10 μl/h; open circles) or exendin (9-39) (100 nmol/24 h; closed circles) on 
heart rate variability (HRV) when animals received cisplatin (5 mg/kg, i.p.). (A) Low frequency (LF), (B) percentage change 
of LF over 24 h, (C) high frequency (HF), (D) percentage change of HF over 24 h, (E) LF/HF, (F) percentage change of LF/HF over 24 h 
are shown. Sal = saline, Ex-9 = exendin (9-39). Data represents the mean ± SEM of 4-6 animals. Significant differences relative to baseline 
recordings of the respective treatment groups are shown as #P<005 (one-way ANOVA or two-way ANOVA as appropriate).
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morphological and neurotransmitter (increase NOS-IR) 
changes within 3 days of administration [49].
Clearly, cisplatin can disrupt digestive tract 
myoelectric activity which is likely to impact contractile 
activity of the gastrointestinal tract. As the relationship 
between the GMA signal (frequency or power) and 
contractile activity of the gastric antrum is not clearly 
defined [50, 51], we are unable to predict the gastric 
motility patterns in either the acute or the delayed phases 
following cisplatin. Recordings of gastric contractile 
activity following cisplatin are rare; in the dog [52], 
studies showed disruption of the inter-digestive motor 
complex (6 h recording) and jejuno-gastric retrograde 
contractions associated with emesis. Studies of the acute 
effect of cisplatin on gastric emptying have only been 
undertaken in rodents where a marked, dose-related, delay 
is reported consistently [53].
Cardiovascular effects of cisplatin and GLP 
receptors
In patients, treatment with cisplatin also causes 
an elevation of HR and decreases HRV during the first 
24 h, suggesting a change in autonomic outflow [54]. A 
link between HRV and nausea has been demonstrated by 
several studies [10, 22, 54]. In this study, the decrease in 
HRV and the shift to “sympathetic dominance” (trend 
to increase the LF/HF ratio; faster heart rate) occurred 
mainly in the acute phase of cisplatin-induced emesis. As 
a general biomarker of ‘nausea’, we would have expected 
HRV to be clearly affected during both phases, but this was 
not the case. This difference in the autonomic outflow to 
the heart between the acute and delayed phase may reflect 
the shift in the underlying mechanisms driving emesis 
from an abdominal vagal afferent dominant pathway to 
the area postrema [28]
Cisplatin-induced vascular toxicities such as 
endothelial injury, myocardial infarction and a reduced 
baroreflex sensitivity have been found after acute 
chemotherapy [55] and this may have posed a problem, 
or compromised the interpretation of HRV data (above). 
Nevertheless, BP normally elevates transiently before 
the onset of retching and/or vomiting, but when data 
were averaged into one hour time periods, cisplatin had 
no overall effect on systolic or diastolic BP during acute 
emesis in the ferret; this is consistent with data from the 
study of emesis during cisplatin-based chemotherapy 
schedules in man [54, 56]. Our long-duration recordings 
extended this knowledge to show that cisplatin also 
does not change BP during the delayed phase of emesis. 
However, HR did decrease, indicating that impaired 
baroreceptor reflex functioning persists into the delayed 
phase of emesis. However, activation of GLP-1 receptors 
has been shown to previously increase BP and HR and 
decrease HRV in ferrets [5] and rats [57, 58]. Further, 
pre-treatment with exendin (9-39) has been shown to 
antagonise the effect of GLP-1 on BP and HR in rats 
[57]. Yet, the present studies found that exendin (9-39) 
significantly elevated blood pressure in cisplatin-treated 
animals. Unfortunately, we did not examine the effect of 
exendin (9-39) administered alone so we do not know if 
BP was affected by exendin (9-39) alone, or was the result 
of an interaction between exendin (9-39) and cisplatin. 
Evidence from other studies showed exendin (9-39) had 
no effect on BP: an acute i.c.v. injection or i.v. infusion of 
exendin (9-39) at 2500 ng did not alter arterial BP or HR 
in rats [57], and i.v. infusion of exendin (9-39) in healthy 
human subjects had no effect on BP [59]. As exendin (9-
39) infusion did not have significant effects on the first 
24 h of recordings, it is possible that long-term infusion 
caused accumulation of exendin (9-39) in the brain, which 
might induce a supra-physiological effect on the BP. It is 
possible, therefore, that the change in BP might be due 
to the combined effect of antagonism of GLP-1 receptors 
and the potential cisplatin-induced cardiovascular 
complications (see above).
Temperature
In the present study, cisplatin also induced 
hyperthermia over 8 h post cisplatin, and this has 
not been reported previously, but related studies 
implicate inflammatory cytokines [60]. After the 
hyperthermic period, hypothermia occurred during 24-
72 h after cisplatin treatment. Hypothermia is reported 
in rats receiving chronic cisplatin treatment [61], but 
the underlying mechanism has not been identified. The 
hypothermic mechanism might be linked to the prolonged 
anorexia caused by cisplatin, as animals might lower body 
temperature to conserve energy during anorexia [62], but 
it could also be related to a marked reduction of activity 
which is noted to occur following cisplatin in the rat [63]. 
Central and peripheral administration of GLP-1 induces 
hypothermia lasting 2 h in rats, but the effect to reduce 
food intake is only seen following its central administration 
[64]. A continuous i.c.v. infusion of exendin-4 also caused 
hypothermia in mice [65], and blockade of central GLP-
1 receptors enhanced LPS-induced fever in rats [66]. In 
the present studies, the continuous infusion of exendin 
(9-39) alleviated the hypothermia caused by cisplatin, 
suggesting a mechanism involving activation of central 
GLP-1 receptors. It is not known if the antagonism of the 
hypothermic action of cisplatin that we observed relate 
to the elevated BP during the delayed phase, where the 
mechanism could reflect a reduction of heat loss secondary 
to any possible vasoconstriction in the skin. Hypothermia 
has been proposed as a biomarker of motion sickness in 
rodents [67], but our failure to observe a consistent pattern 
during acute and delayed emesis indicates that caution 
must be exercised in any interpretation relating to ‘nausea’ 
alone. It is possible that inflammatory mediators that are 
presumed to be released during treatment with cisplatin 
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may elevate temperature, which potentially masks any 
fall in temperature relating to ‘nausea’. In any event, it is 
important to note that the antagonism of hypothermia by 
exendin (9-39) did not impact on the profile of GMA and 
HRV that we recorded during the delayed phase of emesis.
Food intake
Our previous acute experimentation in ferrets 
demonstrated that exendin-4 induces emesis, behaviours 
indicative of nausea (BIN), reduced food intake, 
hypertension, tachycardia, decreased HRV and a reduction 
of gastric slow wave power [24, 25, 68]. BIN and reduced 
food intake could occur independently of emesis or 
activation of the AP and NTS, whereas midbrain and 
forebrain activation were essential for BIN but not emesis, 
as assessed by c-Fos [25]. Conversely, the mechanism of 
cisplatin to reduce food intake in ferrets during the acute 
and delayed phases of emesis is markedly reduced by AP 
ablation [28]. Previous studies in Suncus murinus and 
ferrets have shown that exendin-4-induced emesis and 
BIN, but not the inhibition of food and water intake, can 
be reversed by pre-treatment with exendin (9-39) [5, 25]. 
These findings are consistent with the lack of effect of 
exendin (9-39) on cisplatin-induced reductions in food and 
water intake in the present study, and are comparable to 
studies in Suncus murinus [5].
In addition, a recent rat study showed cisplatin (6 
mg/kg, i.p.) reduced of food intake (at 24 and 48 h) but 
exendin (9-39) (20 μg, i.c.v.) had no effect on the reduced 
food intake or weight loss at 24 h and only a marginal 
improvement at 48 h [69]. Overall, the data from three 
species is consistent in demonstrating that reduced food 
intake induced by cisplatin does not involve central GLP-1 
pathways amenable to blockade by exendin (9-39).
The present study has for the first time 
simultaneously quantified gastric (GMA), cardiovascular 
(BP, HRV) and behavioural (food and water intake) 
effects of cisplatin, in addition to its emetic effects over 
the entire 72 h period encompassing acute and delayed 
emetic phases. The results provide novel insights into 
events that are likely to occur in patients undergoing anti-
cancer chemotherapy. Exendin (9-39) reduced the emetic 
response by ~59 % during the acute phase providing 
evidence that GLP-1 receptors, previously demonstrated to 
be present in key brain regions implicated in emesis in the 
ferret [5], are present in the central pathway(s) resulting 
from the mechanisms (primarily abdominal vagal-
enteroendocrine cell) activated during the acute phase of 
cisplatin-induced emesis [32, 01]. However, caution needs 
to be exerted in pursuing GLP-1 receptor antagonists 
as anti-emetics until the mechanism underlying the 
unexpected hypertensive effect of i.c.v. exendin (9-39) in 
the presence of cisplatin is identified. Cisplatin-induced 
anorexia does not appear to involve central GLP-1 
receptors. Application of MFDFA to GMA data identified 
subtle differences in gastric effects of cisplatin between 
the acute and delayed phases of emesis which may have 
implications for treating the gastrointestinal toxicities of 
chemotherapy. It is unknown if the differences revealed by 
MFDFA contribute to the mechanism of delayed emesis or 
“nausea”. It may be possible that agents with a capacity to 
restore power and structure to slow waves may represent 
a novel class of drug with benefit against the side effects 
of chemotherapeutic challenges.
MATERIALS AND METHODS
Animals
Twelve castrated male fitch ferrets (1.53 ± 0.07 kg) 
were obtained from Southland Ferrets (Invercargill, New 
Zealand) and housed individually in observation cages 
(0.5 m x 0.5 m x 0.5 m) in a temperature-controlled room 
at 24 ± 1°C under artificial lighting, with lights on between 
06.00 to 18.00 h. The relative humidity was maintained at 
50 ± 5 %. Water and food (TriPro super premium chicken 
meal formula dog food, American Nutrition, USA) were 
given ad libitum, unless otherwise stated. All experiments 
were conducted under license from the Government of the 
Hong Kong SAR and the Animal Experimentation Ethics 
Committee, The Chinese University of Hong Kong.
Transmitter implantation and stereotaxic 
surgery for infusion pump implantation
Animals were fasted overnight but allowed 
free access to water. They were then injected with 
buprenorphine (0.05 mg/kg, s.c. Temgesic®), and 
anaesthesia was induced by ketamine (20 mg/kg i.m.; 
Alfasan, Holland). They were intubated using a 2/0 tube, 
and anaesthesia was maintained with 1.5% isoflurane 
(Halocarbon Products Corporation, USA) in oxygen using 
an anaesthetic machine (Narkomed 2C, Drager, USA). 
Rectal temperature was monitored and maintained at 37°C 
using a heating pad (UCI#390 Analogue moist heating 
pad, Rebirth Medical & Design, Inc., Taiwan) and the level 
of anaesthesia was assessed and monitored throughout 
the surgery by the pedal withdrawal reflex. Following a 
midline abdominal incision, the catheter of a C50-PXT 
transmitter (Data Sciences, Inc., USA) was inserted into 
the abdominal aorta up to a length of approximately 2 
cm. A 2 × 2 mm piece of sterile gauze was placed over 
the catheter’s entry point, and fixed with a drop of tissue 
glue. The body of the transmitter was then sutured to 
the left side of the ferret’s abdominal wall muscle with 
the biopotential wires and catheter facing caudally. The 
gastric antrum was exposed and the biopotential wires 
were inserted into the muscle and secured in place by 
serosal sutures. The abdominal cavity was sutured in 
closed layers. The head of the animals was then positioned 
and fixed into a stereotaxic frame equipped with custom-
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made ear-bars and mouthpieces (David Kopf Instruments, 
Tujunga, USA). The temporalis muscles were exposed 
via a skin incision and displaced exposing the skull. A 
hole was drilled in the skull: coordinates for the lateral 
ventricle: 17.3 mm anterior to lambda and 0 mm lateral 
to the midline. A 30-gauge cannula was then inserted into 
the hole 8 mm below the surface of the dura. Two screws 
were fixed on the skull and dental cement was applied 
on the two screws as well as on the guide cannula to fix 
the guide cannula. After fixation, a small incision was 
made at the back of neck, and the end outer tube of the 
iPRECIO™ pump (Primetech Corporation, Tokyo, Japan) 
was tunnelled underneath skin of the neck to the guide 
cannula. Then the end of the outer tube was connected to 
a custom-made bended 30 G needle, and the other end of 
the 30 G needle was inserted into the guide cannula with 
insertion depth identical to the length of guide cannula. 
The inserted needle was fixed by applying dental cement to 
the guide cannula and 30 G needle. After needle fixation, 
two anchors of the pump were sutured to the outside skin 
of the back of the neck by using 3/0 polypropylene suture 
(Prolene® Ethicon). Muscle and skin layers were closed 
respectively with continuous and discontinuous sutures 
of silk thread (2/0) (Mersilk®, Ethicon). The wound 
was sprayed with silicone spray dressing (Opsite®, 
Smith and Nephew, UK). Marbofloxacin (Marbocyl®, 
2 mg/kg, s.c.) was administered once per day for 3 days 
and buprenorphine (0.05 mg/kg, s.c.) was given 8-12 h 
after the first dose. After surgery, animals were housed 
individually in observation cages with free access to food 
and water. They were allowed to recover for at least 7 days 
prior to further experimentation. Recovery was uneventful 
with no indications of infection; food and water intake 
were within the normal range.
Drug treatment protocol
During the recovery period, animals were infused 
i.c.v. with saline at a flow rate of 3 μl/h. On the day of 
experiment, baseline telemetric data were recorded for 24 
h. On the day of drug treatment, at 09.30 h, the saline from 
the pump reservoir was withdrawn, and then the pump 
was refilled with exendin (9-39) (100 nmol, 250 μl; the 
dose was based on our previous studies in ferrets showing 
anti-emetic and hypoglycaemic activity [25, 68]) or saline 
(250 μl). The programmed pump allowed the drug to start 
continuous infusion at 11.00 h with a flow rate of 10 μl/h. 
One hour after the start of drug infusion, cisplatin was 
injected at a dosage of 5 mg/kg, i.p. at 12.00 h; this dose 
has previously been established to reliably induce both 
acute and delayed emesis in the ferret [20]. After cisplatin 
injection, behaviour was recorded for 72 h via a video 
system (Panasonic WV-PC-240, China). Exendin (9-39) 
or saline was refilled twice at 24 and 48 h post cisplatin 
injection. Body weight and food and water intake were 
measured at 24 h intervals.
Data analysis and statistics
Emesis was characterized as rhythmic abdominal 
contractions that were either associated with forceful 
oral expulsion of solid or liquid material from the 
gastrointestinal tract (i.e. vomiting), or not associated 
with passage of material (i.e. retching). Episodes of emesis 
(retching and/or vomiting) were considered separate when 
the animal changed its location in the observation cage, or 
when the interval between retches and/or vomits exceeded 
5s [20].
Telemetric data were analysed using Spike2 
(Version 7, Cambridge Electronic Design). The method 
for analysing GMA is described in previous studies; DP 
was defined as the highest power in the 0 to 15 cpm range, 
and DF was defined as the frequency bin with the highest 
power in the 0 to 15 cpm range [28]. Systolic BP was 
calculated from the peak of the blood pressure recording 
trace and diastolic BP was calculated from the trough. 
Mean arterial BP was defined as systolic BP/3+2*diastolic 
BP/3 [71]. For HR, the peak-to-peak interval was first 
calculated, and HR = 60/P-P interval (bpm). The time-
domain HRV was calculated by taking the standard 
deviation of P-P intervals in 5 min segments [72]. The 
frequency-domain analysis was performed using the FFT. 
The total power of all R-R intervals in 5-min segments 
were determined, along with its LF (0.04-0.15 Hz) and 
HF (0.15-0.7 Hz) components and LF/HF ratio [73]. CBT 
was calculated by taking the average of the data per 5 min 
interval. All data were eventually averaged in 1 h periods 
for statistical analysis.
MFDFA of GMA data for each 24h epoch were also 
performed using Spike 2 following the methodology of 
[74] and [29]. In brief, the magnitude of the multifractality 
in the time series was estimated by the width of the 
spectrum ∆α α α= −max min [31, 75]. 3D plots of 
GMA running spectrum analysis were created using 
OriginPro 9.1.0 (OriginPro 9.1.0, OriginLab Corporation, 
Northampton, USA). For additional details of MFDFA see 
Supplementary Materials.
All statistical analyses were performed using 
GraphPad Prism version 5 (GraphPad Prism version 5.0, 
Inc. California, USA). Differences in behaviour, food 
and water consumption, body weight, mean arterial BP, 
HR, HRV, CBT, GMA and ∆α  between baseline and 
post-cisplatin injection in saline groups were assessed 
using one-way ANOVA followed by a Bonferroni’s 
multiple comparison tests, or by paired Student’s t-tests, 
as appropriate. The difference between the parameters 
measured in saline and exendin (9-39) treated animals 
were assessed using repeated two-way ANOVA and 
Bonferroni tests. All data are expressed as mean ± SEM. 
Differences were considered statistically significant when 
P<0.05.
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Drug formulation
Exendin (9-39) amide (American Peptide Company, 
Sunnyvale, CA) was dissolved in saline (0.9% w/v). 
Cisplatin was purchased as a sterile saline solution at 1 
mg/ml (David Bull Laboratories, Victoria, Australia) and 
injected in a volume of 5 ml/kg.
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